Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams

Critical Care

Pedro Póvoa¹  Joao Gonçalves-Pereira¹ 

[1] CEDOC, Faculty of Medical Sciences, New University of Lisbon, Campo dos Mártires da Pátria, 130, 1169-056 Lisboa, Portugal

关键词: ICU;    pharmacokinetics;    pharmacodynamics;    microdialysis;    β-lactam antibiotics;    dosage;    administration;   

Others  :  1093952
DOI  :  10.1186/cc10441

 received in 2011-05-30, accepted in 2011-09-13,  发布年份 2011

【 摘 要 】

Introduction

Several reports have shown marked heterogeneity of antibiotic pharmacokinetics (PK) in patients admitted to ICUs, which might potentially affect outcomes. Therefore, the pharmacodynamic (PD) parameter of the efficacy of β-lactam antibiotics, that is, the time that its concentration is above the bacteria minimal inhibitory concentration (T > MIC), cannot be safely extrapolated from data derived from the PK of healthy volunteers.

Methods

We performed a full review of published studies addressing the PK of intravenous β-lactam antibiotics given to infected ICU patients. Study selection comprised a comprehensive bibliographic search of the PubMed database and bibliographic references in relevant reviews from January 1966 to December 2010. We selected only English-language articles reporting studies addressing β-lactam antibiotics that had been described in at least five previously published studies. Studies of the PK of patients undergoing renal replacement therapy were excluded.

Results

A total of 57 studies addressing six different β-lactam antibiotics (meropenem, imipenem, piperacillin, cefpirome, cefepime and ceftazidime) were selected. Significant PK heterogeneity was noted, with a broad, more than twofold variation both of volume of distribution and of drug clearance (Cl). The correlation of antibiotic Cl with creatinine clearance was usually reported. Consequently, in ICU patients, β-lactam antibiotic half-life and T > MIC were virtually unpredictable, especially in those patients with normal renal function. A better PD profile was usually obtained by prolonged or even continuous infusion. Tissue penetration was also found to be compromised in critically ill patients with septic shock.

Conclusions

The PK of β-lactam antibiotics are heterogeneous and largely unpredictable in ICU patients. Consequently, the dosing of antibiotics should be supported by PK concepts, including data derived from studies of the PK of ICU patients and therapeutic drug monitoring.

【 授权许可】

   
2011 Gonçalves-Pereira and Póvoa; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26(Suppl 1):S64-S74.
• [2]Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329.
• [3]Póvoa P: Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis 2008, 21:157-162.
• [4]Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003, 17:479-501.
• [5]Estes L: Review of pharmacokinetics and pharmacodynamics of antimicrobial agents. Mayo Clin Proc 1998, 73:1114-1122.
• [6]Pea F, Viale P, Furlanut M: Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034.
• [7]Mehrotra R, De Gaudio R, Palazzo M: Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004, 30:2145-2156.
• [8]Fuster-Lluch O, Gerónimo-Pardo M, Peyró-García R, Lizán-García M: Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008, 36:674-680.
• [9]Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J: A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011, 15:R139. BioMed Central Full Text
• [10]Verdant C, De Backer D: How monitoring of the microcirculation may help us at the bedside. Curr Opin Crit Care 2005, 11:240-244.
• [11]Levitt DG: The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol 2003, 3:3.
• [12]Triginer C, Izquierdo I, Fernandez R, Rello J, Torrent J, Benito S, Net A: Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990, 16:303-306.
• [13]Hansen M, Christrup LL, Jarløv JO, Kampmann JP, Bonde J: Gentamicin dosing in critically ill patients. Acta Anaesthesiol Scand 2001, 45:734-740.
• [14]Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45:755-773.
• [15]Drusano GL: Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007, 45(Suppl 1):S89-S95.
• [16]Mouton JW: Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003, 17:579-598.
• [17]Choi G, Gomersall CD, Tian Q, Joynt GM, Li AM, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif 2010, 30:195-212.
• [18]Shah PM: Parenteral carbapenems. Clin Microbiol Infect 2008, 14:175-180.
• [19]de Stoppelaar F, Stolk L, van Tiel F, Beysens A, van der Geest S, de Leeuw P: Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother 2000, 46:150-151.
• [20]Jaruratanasirikul S, Sriwiriyajan S, Punyo J: Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005, 49:1337-1339.
• [21]Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA: Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002, 19:105-110.
• [22]Lovering AM, Vickery CJ, Watkin DS, Leaper D, McMullin CM, White LO, Reeves DS, MacGowan AP: The pharmacokinetics of meropenem in surgical patients with moderate or severe infections. J Antimicrob Chemother 1995, 36:165-172.
• [23]Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Witebolle X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F: Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126. BioMed Central Full Text
• [24]Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009, 64:142-150.
• [25]Karjagin J, Lefeuvre S, Oselin K, Kipper K, Marchand S, Tikkerberi A, Starkopf J, Couet W, Sawchuk RJ: Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin Pharmacol Ther 2008, 83:452-459.
• [26]Rhomberg PR, Jones RN: Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007, 57:207-215.
• [27]Thalhammer F, Traunmüller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H: Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999, 43:523-527.
• [28]Belzberg H, Zhu J, Cornwell EE, Murray JA, Sava J, Salim A, Velmahos GC, Gill MA: Imipenem levels are not predictable in the critically ill patient. J Trauma 2004, 56:111-117.
• [29]Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR: Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005, 44:539-549.
• [30]Jaruratanasirikul S, Sudsai T: Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion. J Antimicrob Chemother 2009, 63:560-563.
• [31]Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, Sörgel F: Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007, 51:3304-3310.
• [32]Tegeder I, Schmidtko A, Bräutigam L, Kirschbaum A, Geisslinger G, Lötsch J: Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002, 71:325-333.
• [33]Dahyot C, Marchand S, Bodin M, Debeane B, Mimoz O, Couet W: Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin Pharmacokinet 2008, 47:181-189.
• [34]McKindley DS, Boucher BA, Hess MM, Croce MA, Fabian TC: Pharmacokinetics of aztreonam and imipenem in critically ill patients with pneumonia. Pharmacotherapy 1996, 16:924-931.
• [35]Muller-Serieys C, Bergogne-Berezin E, Rowan C, Dombret MC: Imipenem penetration into bronchial secretions. J Antimicrob Chemother 1987, 20:618-619.
• [36]Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, Cerra FB, Zaske DE: Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 1990, 18:37-41.
• [37]Conil JM, Georges B, Mimoz O, Dieye E, Ruiz S, Cougot P, Samii K, Houin G, Saivin S: Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med 2006, 32:2063-2066.
• [38]Bourget P, Lesne-Hulin A, Le Reveillé R, Le Bever H, Carsin H: Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother 1996, 40:139-145.
• [39]Langgartner J, Lehn N, Glück T, Herzig H, Kees F: Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemotherapy 2007, 53:370-377.
• [40]Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, Fazeli MR: Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006, 28:122-127.
• [41]Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmelé T, Chassard D, Saux MC, Allaouchiche B: Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30:976-979.
• [42]Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E: Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob Agents Chemother 1994, 38:2780-2784.
• [43]Boselli E, Breilh D, Rimmelé T, Guillaume C, Xuereb F, Saux MC, Bouvet L, Chassard D, Allaouchiche B: Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med 2008, 36:1500-1506.
• [44]Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Müller M: Impaired target site penetration of β-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001, 29:385-391.
• [45]Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J: Piperacillin penetration into tissue of critically ill patients with sepsis: bolus versus continuous administration? Crit Care Med 2009, 37:926-933.
• [46]Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J: First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2009, 35:156-163.
• [47]Jacolot A, Incagnoli P, Edouard AR, Tod M, Petitjean O, Samii K, Mimoz O: Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1999, 25:486-491.
• [48]Lipman J, Wallis SC, Rickard CM, Fraenkel D: Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001, 27:363-370.
• [49]Lipman J, Wallis SC, Boots RJ: Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 2003, 97:1149-1154.
• [50]Roos JF, Lipman J, Kirkpatrick CM: Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007, 33:781-788.
• [51]Sauermann R, Delle-Karth G, Marsik C, Steiner I, Zeitlinger M, Mayer-Helm BX, Georgopoulos A, Müller M, Joukhadar C: Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005, 49:650-655.
• [52]Joukhadar C, Klein N, Mayer BX, Kreischitz N, Delle-Karth G, Palkovits P, Heinz G, Müller M: Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002, 30:1478-1482.
• [53]Kieft H, Hoepelman AI, Knupp CA, van Dijk A, Branger JM, Struyvenberg A, Verhoef J: Pharmacokinetics of cefepime in patients with the sepsis syndrome. J Antimicrob Chemother 1993, 32(Suppl B):117-122.
• [54]Conil JM, Georges B, Lavit M, Seguin T, Tack I, Samii K, Chabanon G, Houin G, Saivin S: Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance. Int J Clin Pharmacol Ther 2007, 45:529-538.
• [55]Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14:R51. BioMed Central Full Text
• [56]Lipman J, Wallis SC, Rickard C: Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43:2559-2561.
• [57]Bonapace CR, White RL, Friedrich LV, Norcross ED, Bosso JA: Pharmacokinetics of cefepime in patients with thermal burn injury. Antimicrob Agents Chemother 1999, 43:2848-2854.
• [58]Georges B, Conil JM, Seguin T, Dieye E, Cougot P, Decun JF, Lavit M, Samii K, Houin G, Saivin S: Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables. Int J Clin Pharmacol Ther 2008, 46:157-164.
• [59]Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau DP: Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009, 53:1476-1481.
• [60]Roos JF, Bulitta J, Lipman J, Kirkpatrick CM: Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006, 58:987-993.
• [61]Sampol E, Jacquet A, Viggiano M, Bernini V, Manelli JC, Lacarelle B, Durand A: Plasma, urine and skin pharmacokinetics of cefepime in burns patients. J Antimicrob Chemother 2000, 46:315-317.
• [62]Klekner A, Bágyi K, Bognár L, Gáspár A, Andrási M, Szabó J: Effectiveness of cephalosporins in the sputum of patients with nosocomial bronchopneumonia. J Clin Microbiol 2006, 44:3418-3421.
• [63]Boselli E, Breilh D, Duflo F, Saux MC, Debon R, Chassard D, Allaouchiche B: Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med 2003, 31:2102-2106.
• [64]Rondanelli R, Dionigi RV, Regazzi MB, Maurelli M, Calvi M, Mapelli A: Ceftazidime in the treatment of Pseudomonas infections in intensive-care patients. Int J Clin Pharmacol Ther Toxicol 1986, 24:457-459.
• [65]Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE: Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997, 40:269-273.
• [66]Gómez CM, Cordingly JJ, Palazzo MG: Altered pharmacokinetics of ceftazidime in critically ill patients. Antimicrob Agents Chemother 1999, 43:1798-1802.
• [67]Benko AS, Cappelletty DM, Kruse JA, Rybak MJ: Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996, 40:691-695.
• [68]Lipman J, Gomersall CD, Gin T, Joynt GM, Young RJ: Continuous infusion ceftazidime in intensive care: a randomized controlled trial. J Antimicrob Chemother 1999, 43:309-311.
• [69]Boselli E, Breilh D, Rimmelé T, Poupelin JC, Saux MC, Chassard D, Allaouchiche B: Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 2004, 30:989-991.
• [70]Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA: Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000, 179:436-440.
• [71]Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ: Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000, 50:184-191.
• [72]Aubert G, Carricajo A, Coudrot M, Guyomarc'h S, Auboyer C, Zeni F: Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 2010, 32:517-519.
• [73]Georges B, Conil JM, Seguin T, Ruiz S, Minville V, Cougot P, Decun JF, Gonzalez H, Houin G, Fourcade O, Saivin S: Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother 2009, 53:4483-4489.
• [74]Buijk SL, Gyssens IC, Mouton JW, Van Vliet A, Verbrugh HA, Bruining HA: Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. J Antimicrob Chemother 2002, 49:121-128.
• [75]Mouton JW, Punt N, Vinks AA: A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005, 27:762-772.
• [76]Langer M, Cantoni P, Bellosta C, Boccazzi A: Penetration of ceftazidime into bronchial secretions in critically ill patients. J Antimicrob Chemother 1991, 28:925-932.
• [77]Bressolle F, de La Coussaye JE, Ayoub R, Fabre D, Gomeni R, Saissi G, Eledjam JJ, Galtier M: Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother 1992, 36:1404-1411.
• [78]Fridkin SK, Steward CD, Edwards JR, Pryor ER, McGowan JE Jr, Archibald LK, Gaynes RP, Tenover FC, Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Hospitals: Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE Phase 2. Clin Infect Dis 1999, 29:245-252.
• [79]Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, Fourrier F: Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 2002, 28:214-217.
• [80]Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J: Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339.
• [81]Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL: Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010, 25:69-77.
• [82]McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351.
• [83]Gentry LO, Rodriguez-Gomez G: Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob Agents Chemother 1991, 35:2371-2374.
• [84]Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005, 39:32-38.
• [85]Mouton JW, Vinks AA, Punt NC: Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 1997, 41:733-738.
• [86]Nicolau DP: Pharmacodynamic optimization of β-lactams in the patient care setting. Crit Care 2008, 12:S2.
• [87]Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME: Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005, 5:581-589.
• [88]Roberts JA, Webb S, Paterson D, Ho KM, Lipman J: A systematic review on clinical benefits of continuous administration of β-lactam antibiotics. Crit Care Med 2009, 37:2071-2078.
• [89]Ljungberg B, Nilsson-Ehle I: Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother 1992, 36:1437-1440.
• [90]Drusano GL, Standiford HC, Bustamante C, Forrest A, Rivera G, Leslie J, Tatem B, Delaportas D, MacGregor RR, Schimpff SC: Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother 1984, 26:715-721.
• [91]Paradis D, Vallée F, Allard S, Bisson C, Daviau N, Drapeau C, Auger F, LeBel M: Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother 1992, 36:2085-2092.
• [92]Barbhaiya RH, Forgue ST, Gleason CR, Knupp CA, Pittman KA, Weidler DJ, Movahhed H, Tenney J, Martin RR: Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992, 36:552-557.
• [93]Dawson-Saunders B, Trapp RG: Basic & Clinical Biostatistics. 2nd edition. Chicago: Appleton & Lange; 1994.